Overview

Phase II Study of High-Dose Cyclophosphamide in Patients With Refractory Pemphigus

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
OBJECTIVES: I. Determine the response rate and 1-year event-free survival of patients with refractory pemphigus treated with high-dose cyclophosphamide.
Phase:
Phase 2
Details
Lead Sponsor:
Johns Hopkins University
Treatments:
Cyclophosphamide